PT. Penta Valent Tbk (IDX:PEVE)
352.00
-6.00 (-1.68%)
At close: May 26, 2026
PT. Penta Valent Tbk Revenue
PT. Penta Valent Tbk had revenue of 871.41B IDR in the quarter ending March 31, 2026, with 3.73% growth. This brings the company's revenue in the last twelve months to 3.58T, up 14.05% year-over-year. In the year 2025, PT. Penta Valent Tbk had annual revenue of 3.55T with 17.77% growth.
Revenue (ttm)
3.58T
Revenue Growth
+14.05%
P/S Ratio
0.17
Revenue / Employee
3.04B
Employees
1,178
Market Cap
621.50B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 3.55T | 535.25B | 17.77% |
| Dec 31, 2024 | 3.01T | 528.07B | 21.25% |
| Dec 31, 2023 | 2.48T | 337.34B | 15.71% |
| Dec 31, 2022 | 2.15T | 359.31B | 20.10% |
| Dec 31, 2021 | 1.79T | 407.33B | 29.50% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| PT Kalbe Farma Tbk. | 36.21T |
| PT Siloam International Hospitals Tbk | 13.09T |
| PT Mitra Keluarga Karyasehat Tbk | 5.45T |
| PT Sejahteraraya Anugrahjaya Tbk | 2.64T |
| PT Itama Ranoraya Tbk | 1.10T |
| PT Kedoya Adyaraya Tbk | 490.35B |
| PT Indofarma Tbk | 206.24B |
| PT UBC Medical Indonesia Tbk | 205.85B |